Search research articles
Contact Us
Filters
Showing results (131-140 of 174) with videos related to
Page
of 18
Sort By:
JAMA Oncology
|
July 25, 2024
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial
Michael Birrer, Guiling Li, Mayu Yunokawa, et al.
The Medical Journal of Australia
|
May 30, 2021
Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards
Eva Segelov, Christine Carrington, Sanchia Aranda, et al.
Journal for Immunotherapy of Cancer
|
June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
Yoland Antill, Peey-Sei Kok, Kristy Robledo, et al.
Cancers
|
January 8, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)
Deborah Smith, Kristy P Robledo, Sonia Yip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2024
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low
Dione van Dijk, Lisa Vermij, Alicia León-Castillo, et al.
Gynecologic Oncology
|
May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903
Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 27, 2009
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum
Jennifer A Westwood, William K Murray, Melanie Trivett, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 30, 2018
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Aurélie Auguste, Catherine Genestie, Marco De Bruyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2013
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer
Dariush Etemadmoghadam, George Au-Yeung, Meaghan Wall, et al.
Journal of Gynecologic Oncology
|
July 20, 2024
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 174) with videos related to
Sort By:
Page
of 18
JAMA Oncology
|
July 25, 2024
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial
Michael Birrer, Guiling Li, Mayu Yunokawa, et al.
The Medical Journal of Australia
|
May 30, 2021
Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards
Eva Segelov, Christine Carrington, Sanchia Aranda, et al.
Journal for Immunotherapy of Cancer
|
June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
Yoland Antill, Peey-Sei Kok, Kristy Robledo, et al.
Cancers
|
January 8, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)
Deborah Smith, Kristy P Robledo, Sonia Yip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2024
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low
Dione van Dijk, Lisa Vermij, Alicia León-Castillo, et al.
Gynecologic Oncology
|
May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903
Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 27, 2009
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum
Jennifer A Westwood, William K Murray, Melanie Trivett, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 30, 2018
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Aurélie Auguste, Catherine Genestie, Marco De Bruyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2013
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer
Dariush Etemadmoghadam, George Au-Yeung, Meaghan Wall, et al.
Journal of Gynecologic Oncology
|
July 20, 2024
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri, et al.
Page
of 18